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Abstract
Background: The technique of induced sputum has allowed to subdivide asthma patients into inflammatory
phenotypes according to their level of granulocyte airway infiltration. There are very few studies which looked at
detailed sputum and blood cell counts in a large cohort of asthmatics divided into inflammatory phenotypes. The
purpose of this study was to analyze sputum cell counts, blood leukocytes and systemic inflammatory markers in
these phenotypes, and investigate how those groups compared with healthy subjects.
Methods: We conducted a retrospective cross-sectional study on 833 asthmatics recruited from the University
Asthma Clinic of Liege and compared them with 194 healthy subjects. Asthmatics were classified into inflammatory
phenotypes.
Results: The total non-squamous cell count per gram of sputum was greater in mixed granulocytic and neutrophilic
phenotypes as compared to eosinophilic, paucigranulocytic asthma and healthy subjects (p < 0.005). Sputum
eosinophils (in absolute values and percentages) were increased in all asthma phenotypes including paucigranulocytic
asthma, compared to healthy subjects (p < 0.005). Eosinophilic asthma showed higher absolute sputum neutrophil and
lymphocyte counts than healthy subjects (p < 0.005), while neutrophilic asthmatics had a particularly low number of
sputum macrophages and epithelial cells. All asthma phenotypes showed an increased blood leukocyte count
compared to healthy subjects (p < 0.005), with paucigranulocytic asthmatics having also increased absolute blood
eosinophils compared to healthy subjects (p < 0.005). Neutrophilic asthma had raised CRP and fibrinogen while
eosinophilic asthma only showed raised fibrinogen compared to healthy subjects (p < 0.005).
Conclusions: This study demonstrates that a significant eosinophilic inflammation is present across all categories
of asthma, and that paucigranulocytic asthma may be seen as a low grade inflammatory disease.
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Background
The technique of induced sputum has been pivotal in
the emergence of the concept of inflammatory asthma
phenotypes. Although it is technically demanding and
time-consuming, several centers have applied the tech-
nique of induced sputum to characterize asthma inflam-
matory phenotypes in routine [1–7]. It has been
suggested that airway inflammation may be subdivided
into four phenotypes according to the level of granulo-
cyte airway infiltration: eosinophilic, neutrophilic, mixed
granulocytic and paucigranulocytic [2, 3]. This latter has
been considered as a non-inflammatory type of asthma
as the sputum analysis of these patients was suggested
not to differ from healthy subjects [8].
These inflammatory phenotypes have been analyzed
with respect to their demographic, functional and clin-
ical characteristics in several studies [2, 3, 9, 10]. How-
ever, there has been fewer studies looking in detail at
sputum cells [2], blood leukocytes [11], systemic inflam-
matory markers or at these variables in combination in a
large cohort of asthmatics classified according to the ex-
tent of airway granulocytic inflammation, and investigat-
ing how those groups compared with healthy subjects.
Here, in a retrospective analysis, we report on sputum
cell counts, blood leukocytes, C-reactive protein (CRP)
and fibrinogen in a large series of asthmatics seen in
daily practice of a University Clinic and compare the re-
sults with those in healthy subjects.
Our results show that paucigranulocytic asthmatics may
display a low grade airway and systemic inflammation.
Methods
Study design, setting and participants
We conducted a retrospective cross-sectional study on
asthmatic patients and healthy subjects recruited from
the University Asthma Clinic of Liege. Asthmatic pa-
tients were eligible for the study if they had a first visit
with a successful sputum analysis between 1 October
2003 and 5 February 2015. The diagnosis of asthma was
based on the presence of typical symptoms (wheezing,
breathlessness, chest tightness, cough) and at least one
of the following: forced expiratory volume in one second
(FEV1) increase of ≥12 % and 200 ml after inhalation of
400 μg salbutamol or a provocative concentration of
methacholine causing a 20 % fall in FEV1 (PC20M) less
than 16 mg/ml. Atopy was defined by the presence of at
least one positive specific IgE (>0.35 kU/L; Phadia;
Groot-Bijgaarden, Belgium) to one or more common
aeroallergen (cat, dog, grass pollen, tree pollen, house
dust mite and a mixture of moulds). Fractional exhaled
nitric oxide (FENO) measurements were performed at
50 ml/s of flow rate (NIOX, Aerocrine, Sweden). Healthy
subjects were recruited by advertisement and in the hos-
pital staff, during this 12-year period of study. They had
no diagnosis of respiratory disease, a FEV1 ≥ 80 % and a
Tiffeneau index ≥0.7. Only healthy subjects with a suc-
cessful sputum analysis were selected. This retrospective
study was conducted with the approval from the ethics
committee of the University Hospital of Liege (Reference
2015/193). Informed consents were obtained from
healthy subjects. As for asthmatic patients, all procedures
were performed in the context of clinical practice and the
retrospective data collection was conducted with the
approval from the above-mentioned ethics committee.
Sputum induction and analysis
Sputum was induced and processed as previously described
[12]. Briefly, sputum was induced by hypertonic (5 %) or
isotonic saline with salbutamol when post-bronchodilator
FEV1 was >65 % or ≤65 % predicted, respectively. Sputum
was then processed using the whole expectorate technique.
Dithiothreitol (DTT) was used as the mucolytic agent. Spu-
tum sample was considered as adequate for cell count
when squamous cell count was <80 % [13]. Differential cell
count was performed on cytospins after a Diff-Quick
staining.
Asthma phenotypes
Threshold values used to define the eosinophilic and neu-
trophilic phenotypes were a sputum eosinophil count ≥3 %
and a sputum neutrophil count ≥76 %, respectively [14].
The mixed granulocytic phenotype was defined as both
raised sputum eosinophil and neutrophil counts and the
paucigranulocytic one as sputum eosinophil and neutrophil
counts lower than the thresholds.
Statistical analysis
Results were expressed as frequencies and percentages
for categorical variables and as median (interquartile
range) or mean ± standard deviation for continuous var-
iables. Comparisons were performed using a Pearson’s
chi-squared test for categorical variables, an ANOVA or a
Student’s t-test for parametric variables, and a Kruskal-
Wallis test for non-parametric variables. The Pearson
correlation coefficient was used to measure the associ-
ation between the percentage of sputum neutrophils
and eosinophils, and the number of pack-years in asth-
matics. For this parametric test, sputum eosinophils
were logtransformed and the 0 values replaced by 0.1.
A p value <0.05 was considered statistically significant.
When multiple tests were performed, the statistically
significant level was corrected according to the Bonferroni
principle. Statistical analysis was done using STATA
version 13.0 (Statistical Software, College Station, TX:
StataCorp LP).
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Results
Subject characteristics
The demographic, functional and treatment character-
istics of asthmatics and healthy subjects are given in
Table 1. In our cohort of asthmatics with a successful
sputum analysis (n = 833), inflammatory phenotypes
were distributed as follows: 42 % of patients were eo-
sinophilic, 16 % neutrophilic, 4 % mixed granulocytic
and 38 % paucigranulocytic. The group of neutrophilic
asthma presented a higher proportion of women while
eosinophilic asthma had a lower proportion of women.
Paucigranulocytic asthmatics were the youngest and
had the best FEV1 (% predicted) and FEV1/forced vital
capacity (FVC) ratio. All asthma subgroups had a
higher prevalence of atopy as compared to healthy
subjects (p < 0.005: level of statistical significance after
Bonferroni correction).
Sputum cell counts and viability
The sputum cell counts and viability of asthma phe-
notypes and healthy subjects are shown in Table 2.
The total non-squamous cell count per gram of sputum
and the cell viability were greater in mixed granulocytic
and neutrophilic phenotypes compared to eosinophilic,
paucigranulocytic asthma and healthy subjects. Eosinophilic
asthmatics also had significantly greater total sputum cell
counts than paucigranulocytic asthmatics and healthy
subjects. The fraction of squamous cells was less than
20 % in a majority of the patients, and was particu-
larly low in eosinophilic, neutrophilic and mixed
granulocytic asthma. While levels were obviously the
highest in eosinophilic and mixed granulocytic phenotypes
compared to other asthmatics, sputum eosinophils (in ab-
solute values and percentages) were increased in all
asthma phenotypes, compared to healthy subjects (Table 2
and Fig. 1a). Absolute neutrophil counts were increased
not only in neutrophilic and mixed granulocytic asthma,
but also in eosinophilic asthma subjects, compared with
healthy subjects. The group of neutrophilic asthma
was the only one to have a lower absolute sputum
macrophage count than eosinophilic, paucigranulocy-
tic asthmatics and healthy subjects. Absolute sputum
lymphocyte count was greater in eosinophilic asthma
(p < 0.005, versus paucigranulocytic asthma and
healthy subjects), while absolute epithelial cell count
was remarkably lower in case of intense neutrophilic
inflammation (p < 0.005, versus paucigranulocytic and
eosinophilic asthma, Table 2 and Fig. 1b).
Table 1 Demographic, functional and treatment characteristics of asthmatics classified by phenotypes and healthy subjects
Eosinophilic asthma Neutrophilic asthma Mixed granulocytic asthma Paucigranulocytic asthma Healthy subjects p value
N (% of asthmatics) 350 (42) 134 (16) 31 (4) 318 (38) 194 -
Women, N (%) 184 (53) 95 (71)‡† 19 (61) 197 (62) 105 (54) 0.002
Age, years 49 (34–60)* 52 (41–61)‡* 61 (43–71)‡* 43 (30–54) 45 (27–56) 0.0001
BMI 25.9 ± 4.9‡ 25.3 ± 5.4 25.5 ± 4.6 26.1 ± 4.8‡ 24.3 ± 4.1 0.0004
Atopy, N (%) 213 (63)‡ 69 (52)‡ 17 (57)‡ 165 (53)‡ 46 (28) <0.001
Smoking status, N (%)
Non-smokers 190 (54) 73 (55) 19 (61) 162 (52) 109 (57) >0.05
Current smokers 64 (18) 26 (20) 5 (16) 76 (24) 35 (18)
Ex-smokers 96 (27) 33 (25) 7 (23) 75 (24) 47 (25)
FEV1, % predicted 81.2 ± 20.9
‡* 81.6 ± 22.0‡* 81.6 ± 20.6‡ 89.2 ± 18.2‡ 108.0 ± 13.3 0.0001
FEV1/FVC, % 70.7 ± 11.1
‡* 71.7 ± 11.5‡* 70.1 ± 10.5‡* 76.2 ± 9.0‡ 82.1 ± 6.5 0.0001
FENO, ppb 43 (23–82)* 20 (13–33)†§ 36 (21–75)* 16 (12–29) / 0.0001
ICS therapy, N (%) 227 (65) 87 (65) 18 (58) 195 (61) / >0.05
ICS dosea 500 (0–1000) 800 (0–2000) 800 (0–1600) 400 (0–1000) / >0.05
OCS therapy, N (%) 21 (6) 9 (7) 2 (6) 14 (4) / >0.05
LABA, N (%) 209 (60) 80 (60) 20 (65) 181 (57) / >0.05
LTRA, N (%) 75 (21) 37 (28) 9 (29) 73 (23) / >0.05
Theophylline, N (%) 11 (3) 7 (5) 0 (0) 11 (3) / >0.05
‡p < 0.005, comparison with healthy subjects
*p < 0.005, comparison with paucigranulocytic asthma
†p < 0.005, comparison with eosinophilic asthma
§p < 0.005, comparison with mixed granulocytic asthma
aICS dose in beclomethasone dipropionate - chlorofluorocarbon equivalents
Abbreviations: BMI body mass index; FENO fractional exhaled nitric oxide; FEV1 forced expiratory volume in 1 s; FVC forced vital capacity; ICS inhaled corticosteroid;
LABA long-acting β2-agonist; LTRA leukotriene receptor antagonist; OCS oral corticosteroid
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Table 2 Sputum cell counts and viability of asthmatics classified by phenotypes and healthy subjects
Eosinophilic asthma Neutrophilic asthma Mixed granulocytic asthma Paucigranulocytic asthma Healthy
subjects
p value (Kruskal-
Wallis test)Sp. eosinophils ≥3 % Sp. eosinophils <3 % Sp. eosinophils ≥3 % Sp. eosinophils <3 %
Sp. neutrophils <76 % Sp. neutrophils ≥76 % Sp. neutrophils ≥76 % Sp. neutrophils <76 %
Total non-squamous cell count
(× 106/g)
1.18 (0.56–2.85)‡* 1.84 (0.82–5.52)‡*† 4.10 (1.07–12.00)‡*† 0.81 (0.40–2.07) 0.64 (0.37–1.30) 0.0001
Viability (%) 64 (50–75) 79 (68–88)‡*† 81 (67–86)‡*† 64 (48–75) 67 (53–78) 0.0001
Squamous cells (%) 13 (5–25)‡* 12 (3–28)‡* 6 (2–23)‡* 18 (8–35) 18 (10–31) 0.0001
Eosinophils
x 103/g 201 (64–636)‡* 3 (0–27)‡†§ 271 (46–685)‡* 3 (0–10)‡ 0 (0–2) 0.0001
% of non-squamous cells 17.1 (7.4–38.0)‡* 0.2 (0.0–1.0)‡†§ 5.2 (3.4–8.8)‡*† 0.4 (0.0–1.0)‡ 0.0 (0.0–0.4) -
Neutrophils
x 103/g 335 (135–823)‡ 1504 (707–4728)‡*† 3272 (881–10992)‡*† 270 (90–795) 210 (63–563) 0.0001
% of non-squamous cells 33 (16–50)* 87 (82–93)‡*† 83 (79–88)‡*† 42 (21–58) 36 (13–63) -
Macrophages
x 103/g 288 (144–648) 169 (52–425)‡*† 218 (77–607) 337 (167–853) 285 (120–568) 0.0001
% of non-squamous cells 27 (16–43)‡* 9 (4–13)‡*† 6 (3–9)‡*† 46 (29–61) 46 (30–67) 0.0001
Lymphocytes
x 103/g 19 (5–52)‡* 12 (2–41) 19 (0–88) 10 (3–31) 10 (4–26) 0.0012
% of non-squamous cells 1.7 (0.6–3.2) 1.0 (0.3–1.6)‡*† 0.6 (0.0–1.8)‡† 1.4 (0.5–2.8) 1.8 (0.8–3.4) 0.0001
Epithelial cells
x 103/g 56 (20–140)‡ 18 (3–67)‡*† 15 (0–106)*† 50 (23–115)‡ 35 (12–86) 0.0001
% of non-squamous cells 5.0 (2.0–8.6)* 1.0 (0.4–2.0)‡*† 0.6 (0.2–1.8)‡*† 6.0 (2.8–13.0) 4.8 (2.2–11.8) 0.0001
‡p < 0.005, comparison with healthy subjects
*p < 0.005, comparison with paucigranulocytic asthma
†p < 0.005, comparison with eosinophilic asthma

















Blood leukocyte counts and systemic inflammatory markers
The blood leukocyte counts and systemic inflammatory
markers of asthma phenotypes and healthy subjects are
shown in Table 3. All subgroups of asthmatics showed
an increased level of blood leukocytes compared with
healthy subjects (Table 3 and Fig. 2a). As expected, eo-
sinophilic and mixed granulocytic asthmatics had higher
blood eosinophils (in absolute values and percentages)
than neutrophilic, paucigranulocytic asthma and healthy
subjects, but paucigranulocytic asthmatics also showed
higher levels of absolute blood eosinophils than healthy
subjects. Neutrophilic asthmatics had the highest level
of blood neutrophils, compared to eosinophilic, pauci-
granulocytic asthma and healthy subjects, but both eo-
sinophilic and paucigranulocytic asthmatics also had
greater absolute blood neutrophils than healthy sub-
jects. Absolute lymphocyte counts were mainly in-
creased in eosinophilic and paucigranulocytic asthma.
Only the group of eosinophilic asthma had increased
absolute blood basophil counts compared to healthy
subjects. Neutrophilic asthma was characterized by
raised CRP and fibrinogen levels, while eosinophilic
asthma had raised fibrinogen only, compared with























































































Fig. 1 Absolute sputum eosinophils (a) and absolute sputum epithelial cells (b) in asthma phenotypes and healthy subjects. * p < 0.005. Values of
0 were assigned to 0.1 because of the use of a logarithmic scale
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Table 3 Blood leukocyte counts and systemic inflammatory markers of asthmatics classified by phenotypes and healthy subjects
Eosinophilic asthma Neutrophilic asthma Mixed granulocytic asthma Paucigranulocytic asthma Healthy subjectsa p value (Kruskal-
Wallis test)Sp. eosinophils ≥3 % Sp. eosinophils <3 % Sp. eosinophils ≥3 % Sp. eosinophils <3 %
Sp. neutrophils <76 % Sp. neutrophils ≥76 % Sp. neutrophils ≥76 % Sp. neutrophils <76 %
Blood leukocytes (x 103/μL) 7.76 (6.52–8.87)‡ 7.75 (6.43–10.00)‡ 8.02 (6.16–10.83)‡ 7.25 (6.02–8.75)‡ 6.12 (5.03–7.37) 0.0001
Blood eosinophils
/μL 315 (202–513)‡* 129 (79–228)†§ 289 (216–449)‡* 140 (85–227)‡ 106 (68–172) 0.0001
% 4.2 (2.8–6.2)‡* 1.7 (1.0–3.0)†§ 3.9 (2.7–5.8)‡* 2.0 (1.1–3.0) 1.8 (1.0–3.0) 0.0001
Blood neutrophils
/μL 4045 (3204–5140)‡ 4847 (3260–6323)‡*† 4207 (2834–6610) 3971 (3156–5280)‡ 3416 (2610–4188) 0.0001
% 54.0 (47.6–60.1)* 59.5 (52.5–69.3)*† 57.6 (44.4–62.4) 56.5 (50.3–62.2) 54.4 (49.6–62.1) 0.0001
Blood monocytes
/μL 515 (396–667)‡* 492 (408–656)‡ 564 (448–775)‡ 461 (362–608) 399 (330–550) 0.0001
% 6.7 (5.1–8.3) 6.5 (5.4–8.2) 7.2 (5.6–9.0) 6.4 (5.1–8.2) 7.1 (5.7–8.2) >0.05
Blood lymphocytes
/μL 2358 (1918–2809)‡ 2249 (1765–2807) 2180 (1887–2869) 2337 (1894–2904)‡ 2009 (1611–2386) 0.0001
% 31.8 (26.0–38.3) 29.4 (22.5–37.1)‡* 29.1 (21.0–38.2) 32.7 (27.3–38.2) 33.9 (26.5–37.7) 0.006
Blood basophils
/μL 42 (29–63)‡* 35 (23–51)† 39 (27–55) 34 (24–52) 34 (24–46) 0.0001
% 0.6 (0.4–0.8)* 0.5 (0.3–0.6)‡† 0.5 (0.4–0.7) 0.5 (0.3–0.7) 0.5 (0.4–0.8) 0.0001
CRP (mg/L)b 1.4 (0.6–3.6) 1.9 (0.8–5.3)‡ 2.9 (0.6–8.9) 1.6 (0.6–4.5) 1.1 (0.4–2.4) 0.034
Fibrinogen (g/L)c 3.2 (2.8–3.8)‡ 3.2 (2.8–3.7)‡ 3.3 (2.7–3.9) 3.1 (2.7–3.6) 2.9 (2.6–3.2) 0.0008
aData available for 96 healthy subjects
bData available for 208 eosinophilic, 92 neutrophilic, 23 mixed granulocytic, 186 paucigranulocytic and 63 healthy subjects
cData available for 194 eosinophilic, 85 neutrophilic, 21 mixed granulocytic, 174 paucigranulocytic and 59 healthy subjects
‡p < 0.005, comparison with healthy subjects
*p < 0.005, comparison with paucigranulocytic asthma
†p < 0.005, comparison with eosinophilic asthma
§p < 0.005, comparison with mixed granulocytic asthma
















Analysis of asthma phenotypes according to treatment
with inhaled corticosteroids (ICS) and comparison with
healthy subjects
For each phenotype, we compared sputum and blood cell
counts between patients treated and not treated with ICS
and we also compared these subgroups with healthy sub-
jects (Table 4 and Additional file 1: Table S1). In steroid-
naïve paucigranulocytic patients, as in the whole group of
paucigranulocytic asthma, there was an increase in sputum
eosinophil counts, compared to healthy subjects. With re-
spect to systemic inflammation, blood leukocyte, eosinophil
and lymphocyte counts were increased in steroid-naïve
paucigranulocytic asthmatics, compared to healthy subjects
(p < 0.0042: level of statistical significance after Bonferroni
correction, Table 4). Paucigranulocytic asthmatics receiving
inhaled corticosteroids showed an increase in sputum
eosinophils and epithelial cells, and an increase in blood
leukocyte, neutrophil and lymphocyte numbers (p < 0.0042,
Table 4). We did not find any statistically significant differ-
ence between patients treated and not treated with ICS in
the subgroups of paucigranulocytic, neutrophilic and mixed
granulocytic asthma (p > 0.0042, Table 4 and Additional file
1: Table S1). In eosinophilic asthmatics, patients treated
with ICS presented higher levels of sputum epithelial cells,
blood leukocytes and blood neutrophils, as compared with
eosinophilic patients not treated with ICS (p < 0.0042, Add-
itional file 1: Table S1).
Analysis of asthma phenotypes classified with a threshold
of sputum eosinophils of 1.01 %
We also used 1.01 % as the threshold of sputum eosinophils
to define asthma phenotypes. When using this cutoff value,
Fig. 2 Blood leukocytes (a) and blood fibrinogen (b) in asthma phenotypes and healthy subjects. * p < 0.005
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Table 4 Sputum and blood cell counts of non-eosinophilic phenotypes classified by ICS treatment and healthy subjects
Paucigranulocytic asthma,
not treated with ICS
Paucigranulocytic asthma,
treated with ICS
ICS- vs ICS+ Neutrophilic asthma,
not treated with ICS
Neutrophilic asthma,
treated with ICS
ICS- vs ICS+ Healthy subjects
N 123 195 - 47 87 - 194
Sputum total non-squamous cell
count (x 106/g)
0.93 (0.43–2.12) 0.69 (0.36–1.61) NS 1.45 (0.82–4.65)‡ 2.10 (0.75–8.02)‡ NS 0.64 (0.37–1.30)
Sputum viability (%) 65 (48–78) 64 (48–75) NS 78 (68–87)‡ 80 (68–88)‡ NS 67 (53–78)
Sputum squamous cells (%) 16 (7–30) 19 (10–37) NS 18 (5–30) 7 (2–27)‡ NS 18 (10–31)
Sputum eosinophils (x 103/g) 4 (0–15)‡ 2 (0–10)‡ NS 2 (0–28)‡ 4 (0–27)‡ NS 0 (0–2)
Sputum neutrophils (x 103/g) 315 (97–994) 245 (86–710) NS 1197 (707–3776)‡ 1879 (593–7060)‡ NS 210 (63–563)
Sputum macrophages (x 103/g) 451 (188–864)‡ 280 (154–853) NS 127 (33–396)‡ 182 (52–436) NS 285 (120–568)
Sputum lymphocytes (x 103/g) 12 (3–45) 10 (2–24) NS 15 (4–41) 11 (1–39) NS 10 (4–26)
Sputum epithelial cells (x 103/g) 48 (19–113) 52 (25–120)‡ NS 19 (4–44) 18 (3–73) NS 35 (12–86)
Blood leukocytes (x103/μL)a 6.87 (5.85–8.51)‡ 7.47 (6.32–9.06)‡ NS 7.87 (6.41–9.93)‡ 7.71 (6.44–10.06)‡ NS 6.12 (5.03–7.37)
Blood eosinophils (/μL)a 145 (101–217)‡ 139 (74–229) NS 172 (63–293) 123 (80–215) NS 106 (68–172)
Blood neutrophils (/μL)a 3598 (2924–5119) 4211 (3392–5392)‡ NS 4804 (3158–6021)‡ 4885 (3403–6969)‡ NS 3416 (2610–4188)
Blood monocytes (/μL)a 461 (353–592) 463 (370–615)‡ NS 476 (387–648) 519 (419–669)‡ NS 399 (330–550)
Blood lymphocytes (/μL)a 2352 (1891–2967)‡ 2321 (1900–2855)‡ NS 2518 (1989–3035)‡ 2167 (1675–2726) NS 2009 (1611–2386)
Blood basophils (/μL)a 35 (25–52) 33 (24–51) NS 40 (29–53) 33 (22–50) NS 34 (24–46)
a Data available for 96 healthy subjects
‡p < 0.0042, comparison with healthy subjects
















there was no statistically significant difference in sputum
and blood eosinophils (in absolute values and percentages)
between neutrophilic or paucigranulocytic asthma, and
healthy subjects (the level of statistical significance after
Bonferroni correction being a p value <0.005, Table 5).
However, there was a strong trend for greater absolute
sputum eosinophil count in paucigranulocytic asthmatics
versus healthy subjects (p = 0.005). In the paucigranulocy-
tic asthma subgroup defined with this cutoff value, abso-
lute sputum epithelial cells (50 (24-115) × 103/g), blood
leukocytes (7.21 (5.82–8.66) × 103/μL), absolute blood
neutrophils (3900 (3083–5299)/μL) and absolute blood
lymphocytes (2334 (1891–2904)/μL) were still greater
than in healthy subjects (p < 0.005).
Analysis according to atopy
The blood and sputum eosinophil counts of asthmatics and
healthy subjects according to their atopic status are pre-
sented in Table 6. We did not observe any statistically signifi-
cant difference in these cells between atopic and non-atopic
healthy subjects or asthmatics (the level of statistical signifi-
cance after Bonferroni correction being a p value <0.0083).
Analysis according to smoking habits
The proportion of asthma inflammatory phenotypes was
analyzed according to the smoking status of patients
(Fig. 3), and was not different between non-smokers, ex-
smokers and current smokers (p = 0.6). There was how-
ever a correlation between the number of pack-years
and the percentage of sputum neutrophils but this cor-
relation was absent with sputum eosinophils (Fig. 4).
Discussion
Our study shows that the four inflammatory asthma phe-
notypes display raised sputum eosinophilia compared to
healthy subjects. Eosinophilic asthma showed higher levels
of absolute sputum neutrophils and lymphocytes than
healthy subjects, while neutrophilic asthmatics had a
reduced number of sputum macrophages and epithelial
cells. In addition, all phenotypes had increased systemic
inflammation reflected by raised total circulating leukocyte
counts, mainly accounted for by raised granulocytic blood
cell counts compared to healthy subjects.
As previously shown [2], our data indicate that neutro-
philic and mixed granulocytic inflammation is more in-
tense than pure eosinophilic and paucigranulocytic ones
as the total number of cells per gram of sputum was
clearly increased in these two first forms of groups. This
might be related to the larger pool of circulating neutro-
phils and the variety of stimuli able to recruit neutro-
phils into the airways [15]. Our results showing greater
viability in neutrophilic and mixed granulocytic asthma
are also in keeping with those reported by Simpson et al.
[2]. It may seem paradoxical as neutrophils are recog-
nized to be more fragile than eosinophils in cell culture
[16], but this may suggest greater cell turnover and short
time of residency of neutrophils in the airways [17].
It has been suggested that non-eosinophilic asthmatics
are poorly responsive to inhaled corticosteroids [8, 18].
One interesting finding of our study is the fact that the so
called “non-eosinophilic phenotypes” (neutrophilic and
paucigranulocytic phenotypes) actually had more sputum
eosinophils than healthy subjects, pointing to a low grade
Table 5 Eosinophilic inflammation of asthmatics classified by phenotypes (with a sputum eosinophil cutoff of 1.01 %) and healthy
subjects








Wallis test)Sp. eosinophils ≥1.01 % Sp. eosinophils <1.01 % Sp. eosinophils ≥1.01 % Sp. eosinophils <1.01 %
Sp. neutrophils <76 % Sp. neutrophils ≥76 % Sp. neutrophils ≥76 % Sp. neutrophils <76 %
N (% of
asthmatics)
429 (51) 106 (13) 59 (7) 239 (29) 194 -
Sputum
eosinophils
x 103/g 127 (38–471)‡* 0 (0–9)†§ 77 (31–380)‡* 0 (0–5)‡‡ 0 (0–2) 0.0001
% of non-
squamous cells
11.8 (4.0–30.8)‡* 0.0 (0.0–0.5)†§ 3.0 (1.8–6.0)‡*† 0.2 (0.0–0.5) 0.0 (0.0–0.4) 0.0001
Blood
eosinophilsa
/μL 289 (181–444)‡* 123 (62–220)†§ 266 (126–430)‡* 133 (78–200) 106 (68–172) 0.0001
% 3.8 (2.4–5.6)‡* 1.7 (0.9–3.0)†§ 2.9 (1.8–5.6)‡* 1.9 (1.0–2.7) 1.8 (1.0–3.0) 0.0001
aData available for 96 healthy subjects
‡p < 0.005, comparison with healthy subjects
‡‡p = 0.005, comparison with healthy subjects
*p < 0.005, comparison with paucigranulocytic asthma
†p < 0.005, comparison with eosinophilic asthma
§p < 0.005, comparison with mixed granulocytic asthma
Abbreviation: Sp. sputum
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eosinophilic inflammation in these phenotypes. This could
explain the fact that some patients with non-eosinophilic
asthma responded to inhaled corticosteroids in the study
of Cowan et al. [19], even though a limitation of this study
was the absence of placebo-controlled design. Also of
interest is the fact that eosinophilic asthmatics had more
absolute sputum neutrophils compared to healthy subjects.
It is likely to reflect that pathways leading to the recruit-
ment of eosinophils and neutrophils in the airways may
co-exist or act through a same effector in asthma [20].
It is noteworthy that absolute sputum lymphocyte counts
were increased when there was significant eosinophilic infil-
tration. Although little attention has been paid to lympho-
cytes in sputum so far because of their small number
(representing approximately 1–2 %), our finding is in keep-
ing with the role of lymphocytes in organizing eosinophilic
inflammation, a concept which has been established by bron-
chial biopsy and bronchoalveolar lavage analyses [21, 22].
A particularly low absolute number of macrophages was
observed in neutrophilic asthma. Further to this decreased
amount of macrophages in the airways, Simpson et al. [23]
described an impaired capacity of sputum macrophages to
phagocytose apoptotic material in non-eosinophilic asthma,
which may explain chronic inflammation and accumulation
of airway neutrophils.
In keeping with epithelial alteration in asthma [24], we
found an increased epithelial cell number in sputum
from eosinophilic and paucigranulocytic asthma. By con-
trast, epithelial cell count was particularly low in the
groups displaying intense neutrophilic inflammation.
The presence of epithelial cells in sputum samples may
reflect epithelial desquamation. Therefore, it is some-
what surprising to find lower epithelial cell counts in
neutrophilic asthma. Our clinical feeling is that the
cough effort during sputum induction may favor epithe-
lial shedding and our experience is that effort to produce
sputum is less when patients have intense neutrophilic
inflammation, which may prevent epithelial cell
desquamation.
In contrast to COPD [25], little attention has been
paid to systemic inflammation in asthma, so far. Our
data show striking elevation of total blood leukocyte
counts in all asthmatic phenotypes compared to healthy
subjects. There was however no difference between
asthma phenotypes in this respect, which is in keeping
with the recent study of Zhang et al. [11]. Although
raised circulating leukocytes might have been expected
in patients with eosinophilic, neutrophilic and mixed
granulocytic asthma, this finding was somewhat more
surprising in paucigranulocytic asthma.
Fig. 3 Proportion of asthma inflammatory phenotypes according to the smoking status of asthmatics
Table 6 Eosinophilic inflammation of asthmatics and healthy subjects according to atopy
Non-atopic asthmatics Atopic asthmatics Non-atopic healthy subjects Atopic healthy subjects p value (Kruskal-Wallis
test)
N 344 464 118 46 -
Sputum eosinophils
x 103/g 19 (1–173)‡* 34 (3–181)‡* 0 (0–3) 0 (0–4) 0.0001
% of non-squamous cells 1.6 (0.2–9.6)‡* 2.8 (0.2–13.8)‡* 0.0 (0.0–0.4) 0.0 (0.0–0.5) 0.0001
Blood eosinophilsa
/μL 188 (109–327)‡ 217 (124–375)‡* 93 (62–135) 134 (80–202) 0.0001
% 2.6 (1.4–4.0)‡ 3.0 (1.7–4.7)‡ 1.5 (0.9–2.9) 2.1 (1.6–3.0) 0.0001
aData available for 54 non-atopic healthy subjects and 31 atopic healthy subjects
‡p < 0.0083, comparison with non-atopic healthy subjects
*p < 0.0083, comparison with atopic healthy subjects
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As previously shown [3, 11], patients with a raised
sputum eosinophilic inflammation also had the highest
levels of blood eosinophils (absolute values or percent-
ages). Moreover, we found that the highest levels of ab-
solute blood neutrophils were observed in neutrophilic
and mixed granulocytic asthma, although the results did
not reach statistical significance in this last phenotype,
probably due to the small number of patients. Interest-
ingly, paucigranulocytic asthmatics also had raised abso-
lute circulating eosinophils and neutrophils compared to
healthy subjects. Overall it points to a granulocytic in-
flammation in all asthma phenotypes.
Like in sputum, absolute lymphocyte counts were in-
creased in blood of patients with eosinophilic asthma.
Interestingly, levels of absolute blood basophils were also
higher in these patients, which is consistent with a previ-
ous report showing a concomitant increase in circulating
eosinophils and basophils after allergen inhalation in
atopic asthmatics [26].
Supporting the concept of low grade systemic inflam-
mation in asthma, we found a mild but significant
increase in fibrinogen levels in eosinophilic and neutro-
philic asthma, while increase in CRP was essentially ob-
served in asthmatics with intense airway neutrophilic
infiltration, as previously shown [27].
The group of paucigranulocytic asthmatics may be con-
sidered heterogeneous as almost two third of the patients
were receiving ICS, which may have attenuated an airway
inflammation initially present before the start of the treat-
ment. Therefore, it is interesting to notice that mild airway
and systemic eosinophilic inflammation, together with
raised circulating lymphocyte number, were still present in
those patients not treated with ICS. One limitation of our
study is the retrospective design that precludes any further
phenotypic characterization of circulating lymphocytes.
Several interventional studies have shown that ICS
therapy decreases sputum eosinophils [28, 29] and in-
creases sputum neutrophils [19]. In our study, we did
not find any statistically significant difference in these
sputum cells between patients treated and not treated
with ICS. However, because of its cross-sectional design,
our study does not question the impact of ICS on eo-
sinophil and neutrophil counts. We believe that the per-
sistence of significant sputum eosinophilia in ICS treated
asthmatics reflects the severity of the inflammatory
process in these patients.
Paucigranulocytic asthma is defined as a sputum eosino-
phil count <3 % in our study. Others have proposed a
cutoff at 1.01 % [2]. When choosing this cutoff in our
patients, we increase the proportion of eosinophilic
asthma from 42 to 51 % and we correspondingly de-
crease the proportion of paucigranulocytic asthma from
38 to 29 %. With this cutoff at 1.01 %, the group of pauci-
granulocytic asthmatics still displayed signs of airway and
systemic inflammation, although they did not show in-
creased circulating blood eosinophils anymore. It is in-
teresting to postulate that the paucigranulocytic
phenotype may be composed of some asthmatics pre-
senting low grade inflammation and others without any
sign of airway and systemic inflammation.
Some studies have shown that the eosinophilic inflam-
mation is somewhat related to atopy [3, 30]. Our data
suggest that the eosinophilic trait observed in all asthma
phenotypes is independent of the atopic status with
non-atopic asthmatics not displaying statistically differ-
ent sputum and blood eosinophil counts from their
atopic counterparts.
There was no significant change in the proportion of
inflammatory phenotypes according to the smoking sta-
tus. However, in contrast to sputum eosinophils, sputum
Fig. 4 Relationship between sputum neutrophils (a) and eosinophils (b) and the number of pack-years in ex- and current smoker asthmatics. For
sputum eosinophils, values of 0 were assigned to 0.1 because of the use of a logarithmic scale
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neutrophil count appears to be partly associated with
the cumulative smoking history expressed as pack-years.
Previous studies failed to find this relationship [31, 32]
but they were performed on a limited number of pa-
tients. This association remains however rather limited
based on our results, where pack-years can only account
for 5 % of the neutrophil variability.
It is known that asthma inflammatory phenotypes may
somewhat vary over time [2, 33]. One limitation of our
study is its cross-sectional design with sputum analyzed
at only one time point.
Conclusions
Overall, this study demonstrates that a significant eo-
sinophilic inflammation is present across all categories
of asthma, and that paucigranulocytic asthma may be
seen as a low grade inflammatory disease. Whether
steroid-naïve or a part of steroid-treated paucigranulocy-
tic asthmatics may do without ICS should be investi-
gated in long term trials, but our data incite to be
cautious in clinical practice for now.
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